| Literature DB >> 35335631 |
Sara Ceballos1, Carmen Lozano1, Carmen Aspiroz2, Laura Ruiz-Ripa1, Paula Eguizábal1, Allelen Campaña-Burguet1, Emilia Cercenado3, Ana Isabel López-Calleja4, Javier Castillo5, Jose Manuel Azcona-Gutiérrez6, Luis Torres7, Jorge Calvo8, Carmen Martin9, María Navarro10, Myriam Zarazaga1, Carmen Torres1.
Abstract
Tetracycline resistance (TetR) has been evidenced as a good phenotypic marker for detection of livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) isolates of the clonal complex CC398. The aim of this study was to characterise a collection of 95 TetR-MRSA isolates, not belonging to the lineage CC398, that were obtained in a previous multicentre study, to detect other MRSA clonal complexes that could be associated with this phenotypic TetR marker. The TetR-MRSA isolates were recovered from 20 Spanish hospitals during 2016 and they were characterised to determine their antimicrobial resistance and virulence phenotypes/genotypes as well as the presence of the immune evasion cluster (IEC). A high proportion of isolates belonging to the CC1 lineage (46%) were observed, as well as to the CC5, CC8 and CC45 lineages (11% each one). Thirty-two different spa-types were identified, being predominantly CC1-t127 (40%) and CC45-t1081 (11%). The IEC system (with the gene scn as marker) was present in 73% of isolates and 16% produced the Panton Valentine leucocidin (PVL). A high proportion of MRSA-CC1 isolates were scn-negative (38.6%) and 52.9% of them were blaZ-negative. A multidrug resistance (MDR) phenotype was identified in 86% of MRSA isolates. The knowledge of other TetR-MRSA genetic lineages, in addition to CC398, is highly relevant, since most of them were MDR and some of them presented important virulence factors. Strains potentially associated with livestock (as the subpopulation CC1-t127-scn-negative) or with humans (as the CC45 lineage or the subpopulation CC1-scn-positive) have been found in this study. The use of tetracycline-resistance for detection, not only of CC398 but also of other LA-MRSA lineages should be tracked in the future.Entities:
Keywords: CC1; CC398; MRSA; multicentre study; t127; tetracycline resistance
Year: 2022 PMID: 35335631 PMCID: PMC8956062 DOI: 10.3390/pathogens11030307
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Distribution of non-CC398 TetR-MRSA isolates among hospitals and genetic lineages detected.
| Hospital Number a | Number of Isolates | Rates (%) | Density (per km2) | Clonal Complex | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSA | TetR-MRSA | TetR-MRSA CC398 | TetR-MRSA Non-CC398 | TetR-MRSA CC1 | TetR-MRSA/ | TetR-MRSA Non-CC398/TetR-MRSA | TetR-MRSA | TetR-MRSA CC1/TetR-MRSA Non-CC398 | Pigs | Inhabitants | + | − | ||
| H1 | 87 | 33 | 27 | 6 | 6 | 38 | 18 | 18 | 100 | 247.46 | 717.36 | 6 | 0 | CC1 (6) |
| H2 | 135 | 20 | 19 | 1 | 0 | 15 | 5 | 0 | 0 | 217.68 | 14.05 | 1 | 0 | CC45 (1) |
| H3 | 328 | 24 | 15 | 9 | 1 | 7 | 38 | 4 | 11 | 217.68 | 14.05 | 8 | 1 | CC1 (1), CC45 (8) |
| H4 | 251 | 34 | 18 | 16 | 12 | 14 | 47 | 35 | 75 | 142.66 | 55.20 | 8 | 8 | CC1 (12), CC5 (1), CC8 (2), |
| H5 | 175 | 20 | 9 | 11 | 5 | 11 | 55 | 25 | 45 | 142.66 | 55.20 | 10 | 1 | CC1 (5), CC5 (1), CC8 (1), CC45 |
| H6 | 76 | 9 | 7 | 2 | 2 | 12 | 22 | 22 | 100 | 142.66 | 55.20 | 1 | 1 | CC1 (2) |
| H7 | 42 | 6 | 3 | 3 | 2 | 14 | 50 | 33 | 67 | 142.66 | 55.20 | 1 | 2 | CC1 (2), CC80 (1) |
| H8 | 36 | 4 | 4 | 0 | 0 | 11 | 0 | 0 | 0 | 69.97 | 9.15 | - | - | - |
| H9 | 36 | 2 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 50.89 | 61.90 | - | - | - |
| H10 | 206 | 14 | 7 | 7 | 3 | 7 | 50 | 21 | 43 | 50.89 | 61.90 | 5 | 2 | CC1 (3), CC8 (1), CC80 (1), |
| H11 | 84 | 7 | 3 | 4 | 2 | 8 | 57 | 29 | 50 | 42.10 | 138.18 | 3 | 1 | CC1 (2), CC8 (2) |
| H12 | 220 | 6 | 3 | 3 | 1 | 3 | 50 | 17 | 33 | 27.66 | 25.54 | 3 | 0 | CC1 (1), CC8 (1), unknown (1) |
| H13 | 42 | 2 | 0 | 2 | 0 | 5 | 100 | 0 | 0 | 27.66 | 25.54 | 0 | 2 | CC5 (2) |
| H14 | 112 | 6 | 4 | 2 | 1 | 5 | 33 | 17 | 50 | 18.31 | 62.51 | 0 | 2 | CC1 (1), CC8 (1) |
| H15 | 334 | 5 | 5 | 0 | 0 | 1 | 0 | 0 | 0 | 40.99 | 107.53 | - | - | - |
| H16 | 130 | 7 | 3 | 4 | 0 | 5 | 57 | 0 | 0 | 30.56 | 360.18 | 3 | 1 | CC8 (1), CC88 (1), unknown (2) |
| H17 | 315 | 12 | 0 | 12 | 4 | 4 | 100 | 33 | 33 | 20.85 | 810.66 | 12 | 0 | CC1 (4), CC5 (2), CC7 (1), |
| H18 | 277 | 7 | 3 | 4 | 2 | 3 | 57 | 29 | 50 | 20.19 | 517.95 | 0 | 4 | CC1 (2), CC5 (1), CC30 (1) |
| H19 | 371 | 13 | 5 | 8 | 2 | 4 | 62 | 15 | 25 | 00.45 | 109.06 | 7 | 1 | CC1 (2), CC5 (3), CC8 (1), CC30 (1), CC88 (1) |
| H20 | 126 | 1 | 0 | 1 | 1 | 1 | 100 | 100 | 100 | 00.45 | 109.06 | 1 | 0 | CC1 (1) |
| Total | 3383 | 232 | 137 b | 95 | 45 | 6.8 | 40.9 | 13.4 | 47.4 | - | - | 69 | 26 | - |
a Numeric code used for the analysed hospitals (H). H1: H. Universitari de Vic; H2: H. de Barbastro; H3: H. San Jorge; H4: H. Universitario Miguel Servet; H5: H. Universitario Lozano Blesa; H6: H. Royo Villanova; H7: H. Ernest Lluch Martin; H8: H. de Alcañiz; H9: Clínica Universitaria de Navarra; H10: Complejo Hospitalario de Navarra; H11: H. Virgen Macarena; H12: H. Universitario de Burgos; H13: H. Santiago Apóstol; H14: H. San Pedro; H15: H. Universitario de Álava; H16: H. Universitario de Donostia; H17: H. Universitario Gregorio Marañón; H18: H. de Galdakao; H19: H. Marqués de Valdecilla; H20: H. Sierrallana. b These strains were previously characterised [14]. c scn: presence or absence of the scn gene as marker of the immune evasion cluster (IEC).
Molecular characterisation of the non-C398 TetR-MRSA collection (n = 95) attending to their spa-types and sample origin.
| Clonal Complex (CC) (%) | No of Isolates | Sample Origin (No of Isolates) |
| PVL+ h | |
|---|---|---|---|---|---|
| CC1 (46%) | t127 | 38 | SSTI b (17), ES c (11), RTI d (5), blood (3), UTI e (1), SSI f (1) | 23 | 1 |
| t174, t693 | 2 | SSTI | 2 | 0 | |
| t1381 | 2 | ES (1), RTI (1) | 1 | 0 | |
| t1784 | 1 | Blood | 1 | 1 | |
| t2207 | 1 | ES | 0 | 0 | |
| CC5 (11%) | t002 | 5 | SSTI (2), ES (2), UTI (1) | 4 | 0 |
| t067 | 3 | SSTI (2), UTI (1) | 1 | 0 | |
| t688 | 1 | RTI | 1 | 0 | |
| t1594 | 1 | ES | 1 | 0 | |
| CC7 (1%) | t091 | 1 | SSTI | 1 | 0 |
| CC8 (11%) | t008 | 1 | SSTI | 1 | 1 |
| t064, t1476 | 2 | RTI | 2 | 0 | |
| t148 | 6 | SSTI (5), ES (1) | 3 | 2 | |
| t2849 | 1 | RTI | 0 | 0 | |
| CC30 (2%) | t665 | 2 | SSTI (1), SSI (1) | 1 | 2 |
| CC45 (11%) | t1081 | 10 | SSTI (6), ES (2), SSI (1), RTI (1) | 10 | 0 |
| CC80 (2%) | t044 | 1 | SSTI | 1 | 1 |
| t088 | 1 | SSTI | 1 | 0 | |
| CC88 (3%) | t690 | 2 | RTI | 2 | 2 |
| t4103 | 1 | UTI | 1 | 1 | |
| CC121 (1%) | t17234 a | 1 | SSTI | 1 | 1 |
| ST2625 (2%) | t17235 a | 2 | SSTI | 2 | 0 |
| ST5427 a (1%) | t17236 a | 1 | SSTI | 1 | 0 |
| Unknown (11%) | t437 | 1 | RTI | 1 | 1 |
| t992 | 1 | SSI | 1 | 0 | |
| t1354 | 1 | SSTI | 1 | 1 | |
| t1954, t3324 | 2 | SSTI | 2 | 0 | |
| t4725 | 2 | RTI | 0 | 1 | |
| t10419 | 3 | SSTI | 3 | 0 |
a New spa-type or sequence type; b SSTI: skin and soft tissue infections; c ES: epidemiological surveillance; d RTI: respiratory tract infections; e UTI: urinary tract infections; f SSI: surgical site infection; g scn+: presence of the scn gene as marker of the immune evasion cluster (IEC); h PVL+: presence of the genes encoding Panton–Valentine leukocidin.
Characterisation of tetracycline-resistant CC1 MRSA isolates (n = 44).
| Antimicrobial Resistance (Non Beta-Lactams) | No of | No of | No of PVL Positive Isolates | Origin (No of Isolates) c | ||
|---|---|---|---|---|---|---|
| Phenotype a (No of Isolates) | Genotype b | |||||
| t127 (38) | TET (5) |
| 4 | 1 | 0 | ES (5) |
| ERY-TET (6) | 6 | 1 | 0 | RTI (1), SSTI (5) | ||
| CLI-ERY-TET (17) | 11 | 8 | 1 | ES (3), RTI (3), SSTI (7), SSI (1), blood (3) | ||
| CIP-TET (1) |
| 1 | 0 | 0 | ES (1) | |
| ERY-CIP-TET (1) |
| 1 | 1 | 0 | RTI (1) | |
| CLI-ERY-CIP-TET (5) | 4 | 2 | 0 | ES (1), SSTI (3), UTI (1) | ||
| TOB-CLI-ERY-TET (1) |
| 1 | 0 | 0 | SSTI (1) | |
| TOB-CLI-ERY-MUP-TET (2) |
| 1 | 2 | 0 | ES (1), SSTI (1) | |
| t1381 (2) | TET (1) |
| 0 | 1 | 0 | RTI (1) |
| CLI-ERY-CIP-TET (1) |
| 1 | 0 | 0 | RTI (1) | |
| t174 (1) | CIP-TET (1) |
| 1 | 0 | 0 | SSTI (1) |
| t693 (1) | TET (1) |
| 0 | 0 | 0 | SSTI (1) |
| t1784 (1) | ERY-TOB-TET (1) |
| 1 | 0 | 1 | Blood (1) |
| t2207 (1) | CLI-ERY-MUP-CIP-TET (1) |
| 1 | 1 | 0 | RTI (1) |
a TET, tetracycline; ERY, erythromycin; CLI, clindamycin; CIP, ciprofloxacin; MUP, mupirocin; b A number in superscript reflects the number of isolates of the group that has the referred characteristic; c ES: epidemiological surveillance; RTI: respiratory tract infections; UTI: urinary tract infections; SSI: surgical site infection.
Figure 1Presence of immune evasion cluster (IEC) among TetR-MRSA non-CC398 isolates: (A) Presence or absence of IEC according to the clonal complexes (CCs) of the isolates; (B) Presence or absence of the IEC in PVL-positive isolates according to their clonal complexes (CCs).
Figure 2Statistically significant differences found in the characterisation of our TetR-MRSA non-CC398 isolates. (A) Absence of scn in CC1 and non-CC1 isolates; (B) MDR detection in clinical and epidemiological surveillance samples; (C) Detection of the ermB gene in erythromycin-clindamycin constitutive resistant (ERYR-cCLIR) and erythromycin-clindamycin (ERYR-iCLIR) inducible resistant isolates. * p ≤ 0.05.
Figure 3Antimicrobial resistance phenotype and genotype detected among TetR-MRSA non-CC398 isolates. (A) Antimicrobial resistance phenotype (ERY, erythromycin; CLI, clindamycin; CIP, ciprofloxacin; FUS, fusidic acid; MUP, mupirocin); (B) Antimicrobial resistance genotype.
Figure 4Presence or absence of the resistance blaZ gene in CC1 and non-CC1 tetracycline-resistant MRSA isolates according to the presence or absence of the IEC (scn gene).
Macrolide-lincosamide resistance phenotypes among TetR-MRSA isolates and resistance genes detected a,b.
| Phenotype |
|
|
|
|
|
|
|
|
| No of Isolates |
|---|---|---|---|---|---|---|---|---|---|---|
| ERYR-CLIS | − | − | − | − | + | − | − | − | − | 19 |
| ERYR-cCLIR | − | − | + | − | + | − | − | − | − | 5 |
| − | − | + | − | − | − | − | − | − | 3 | |
| − | + | + | − | − | − | − | − | − | 2 | |
| − | + | − | − | + | − | − | − | − | 2 | |
| + | + | − | − | + | + | − | + | − | 1 | |
| − | + | − | − | + | − | − | + | − | 1 | |
| − | + | + | − | − | − | − | + | − | 1 | |
| − | − | + | − | + | + | − | − | − | 1 | |
| ERYR-iCLIR | − | − | + | − | − | − | − | − | − | 25 |
| − | − | + | − | + | − | − | − | − | 4 | |
| − | − | + | − | + | + | − | − | − | 1 | |
| − | + | − | − | + | − | − | − | − | 1 | |
| − | + | − | − | + | − | − | + | − | 1 | |
| − | − | − | − | − | − | − | − | − | 1 |
a Genes tested: ermA, ermB, ermC, ermT, msrA, linA, linB, lsaB and vgaA. b Symbols: +: positive result; −: negative result.